| Database ID | Agent | Target | Cancer Type | Detail |
| DB00136 | MSC2156119J | Hepatocyte growth factor receptor | liver cancer | view |
| DB00137 | golvatinib | cMet and Eph receptor | advanced solid tumors | view |
| DB00138 | golvatinib | cMet and Eph receptor | liver cancer | view |
| DB00139 | foretinib | Vascular endothelial growth factor receptor 2
Hepatocyte growth factor receptor | liver cancer | view |
| DB00140 | ENMD2076 | Aurora kinase A | advanced solid tumors | view |
| DB00141 | MK2206 | AKT1 protein kinase | advanced solid tumors | view |
| DB00142 | MK2206 | AKT1 protein kinase | advanced solid tumors | view |
| DB00143 | MK2206 | AKT1 protein kinase | advanced solid tumors | view |
| DB00144 | BIBF 1120 | VEGFR 13, FGFR 13, PDFGR ¦Á and ¦Â | advanced solid tumors | view |
| DB00145 | BIBF 1120 | VEGFR 13, FGFR 13, PDFGR ¦Á and ¦Â | non small cell lung cancer | view |
| DB00146 | BAY 869766 | Dual specificity mitogenactivated protein kinase kinase | liver cancer | view |
| DB00147 | trametinib | MEK2
Dual specificity mitogenactivated protein kinase kinase 1 | advanced solid tumors | view |
| DB00148 | trametinib | MEK2
Dual specificity mitogenactivated protein kinase kinase 1 | advanced solid tumors | view |
| DB00149 | trametinib | MEK2
Dual specificity mitogenactivated protein kinase kinase 1 | advanced solid tumors | view |
| DB00150 | CC223 | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |